top of page
Search

Insulet: New product cycle

  • Writer: Abacus Research
    Abacus Research
  • Sep 17, 2024
  • 1 min read

Insulet is a ~$17b market cap insulin pump leader.

  1. The primary bet is the Omnipod 5 driven product cycle:The approvals / product launches are mostly done, it is now just a question of execution and market demand.

  2. Insulet’s has seen significant devaluation on the back of GLP-1s.

    • The secondary bet is that the ‘negative’ impact of GLP-1s is negligible over the next decade. If this is proven, the multiple should expand

    • Note that GLP1s have no impact on type 1 diabetes, insulet’s core customer.


In our upside scenario we see a path to $3.6bn in 2027 revenues (2023-27 CAGR of 21%) and an EPS of $6.50 (25% CAGR), with EPS ~10% above consensus.


Potential Upside:     $320 (+37%)

Sensible Downside: $195(-16%)


 
 
 

Recent Posts

See All
Figure (FIGR)

We believe Figure is highly disruptive. If tokenisation of real-world assets is a theme for the next decade, FIGR could be at the centre of it. Figure has found a real-world use for blockchain, provin

 
 
 
Circle and Stablecoins

The Genius Act has changed the U.S.’s relationship with crypto, making the US the most attractive country in the world for stablecoins....

 
 
 

Comments

bottom of page